Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 451 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Norvir Clear all
Completed Phase 1 Interventional

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Nevirapine
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Beverly Hills, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2009 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

NCT01896622
View directory record Official record
Conditions
HIV
Interventions
Ritonavir, Cobicistat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations

NCT00697892
View directory record Official record
Conditions
HIV Infections, Malaria
Interventions
lopinavir/ritonavir, efavirenz, artemether/lumefantrine
Drug
Lead sponsor
Fran Aweeka
Other
Eligibility
21 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 4 Interventional

Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

NCT00084253
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir/ Stavidine / Lamivudine, Atazanavir-Ritonavir/ Stavidine / Lamivudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Call For Information, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 5, 2010 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

NCT00044837
View directory record Official record
Conditions
HIV Infections
Interventions
Medroxyprogesterone acetate, Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)

NCT01276236
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

NCT01519336
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, darunavir, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926
View directory record Official record
Conditions
HIV Infections
Interventions
Once daily
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients

NCT00116636
View directory record Official record
Conditions
HIV Infections
Interventions
Kaletra
Drug
Lead sponsor
Therapeutic Concepts
Other
Eligibility
18 Years and older
Enrollment
40 participants
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

NCT00909311
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-450, ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

NCT00001083
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Ritonavir, Nevirapine, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

NCT00855088
View directory record Official record
Conditions
HIV/AIDS, HIV Infections
Interventions
darunavir, Ritonavir, Etravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

NCT02511431
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 4 Interventional Results available

Lopinavir/Ritonavir (Kaletra) PK in Children

NCT00810108
View directory record Official record
Conditions
HIV/AIDS Treatment, HIV Infections
Interventions
lopinavir/ritonavir (Kaletra®) tablets
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Years to 17 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
San Diego, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

NCT01221298
View directory record Official record
Conditions
Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
Interventions
ABT-450, ABT-072, Ribavirin, Ritonavir
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug Interaction Study

NCT00646776
View directory record Official record
Conditions
Antivirals/HIV
Interventions
Rifabutin, Rifabutin + Atazanavir + Ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

NCT00260078
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

NCT00006604
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
91 Days to 21 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

NCT05668091
View directory record Official record
Conditions
Long COVID
Interventions
Nirmatrelvir, Ritonavir, Placebo
Drug
Lead sponsor
Harlan M Krumholz
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 20, 2026, 9:54 AM EDT